Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06013371 · ClinicalTrials.gov registry record · Phase 2
PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Terminated
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT06013371 is a Phase 2 study that was terminated before completion, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 32 participants.
The verdict
NCT06013371, a Phase 2 study, was terminated before completion, sponsored by Icahn School of Medicine at Mount Sinai.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai. The study will include 33-39 adult subjects with moderate-to-severe-Seborrheic dermatitis (SD) as well as 33-39 adult subjects with moderate-to-severe papulopustular rosacea (PPR). Subjects will be randomized 2:1 to receive study drug or placebo. Enrolled subjects will apply topical PF-07038124 0.02% ointment once daily for 8 weeks. They will return for visits at weeks 4, 8, and 12 following study treatment initiation for repeat clinical assessments, medication reviews, tape-strip, blood and urine sample collections, and monitoring for adverse events.
Interventions
- DRUG Placebo Ointment
- DRUG PF-07038124
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2023-07-19 |
| Est. Completion | 2025-02-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06013371
The ClinicalTrials.gov registry entry for NCT06013371 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Ointment is the first listed.
NCT06013371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06013371 about?
NCT06013371 is a clinical study titled "PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea". This study is a double-blind, vehicle-controlled clinical trial. The study will take place at Icahn School of Medicine at Mount Sinai. The study will include 33-39 adult subjects with moderate-to-severe-Seborrheic dermatitis (SD) as well as 33-39 adult subjects with moderate-to-severe papulopustular...
What is the current status of trial NCT06013371?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2023-07-19. Estimated completion is 2025-02-18.
What interventions are being tested in trial NCT06013371?
The interventions under investigation include: Placebo Ointment (DRUG), PF-07038124 (DRUG).
Who is sponsoring clinical trial NCT06013371?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.